Contract Manufacturing, Finished Drug Product

Hovione Expands Capacity Globally

November 11, 2021

Hovione will invest $170 million in new capacity and capabilities in Portugal, Ireland, and New Jersey

Considerations for DPIs and MDIs in Inhalation Drug Delivery

October 15, 2021

Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery.

MedPharm Opens Manufacturing Facility for Topical and Transdermal Drug Products

June 04, 2021

MedPharm’s new facility for process development and small-scale manufacturing is in North Carolina, near its existing R&D center.

Quotient Sciences Acquires CDMO Arcinova

February 17, 2021

The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.

Meeting Fill/Finish Challenges for COVID-19 Vaccines

February 02, 2021

CDMOs address the unique challenges of liquid and lyophilized forms as well as preparing for the large capacity needed for COVID-19 vaccines.

Piramal Pharma Solutions Opens Oral Solid Dosage Drug Product Facility

September 23, 2020

CMDO Piramal Pharma Solutions held a grand opening at a facility they acquired in Sellersville, PA.

Gaining Experience in Continuous Manufacturing

August 14, 2020

Experts at Hovione describe progress being made in understanding how to optimize continuous processes for oral solid-dosage drug products.

Vetter Expands Fill/Finish Capacity with Acquisition of New Site in Austria

July 08, 2020

The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.

BARDA Funds US-based Drug Manufacturing Initiative

May 19, 2020

HHS announces $354 million in funding for private industry to manufacture generic drugs in the US from raw materials to finished product.

Catalent to Manufacture J&J’s Lead COVID-19 Vaccine Candidate

April 30, 2020

Catalent and Johnson & Johnson announce joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.